NTEG- Bloodless Glucose Monitor Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTEG- Bloodless Glucose Monitor

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brander who wrote (66)	10/10/1997 4:28:00 PM
From: Jim Lovejoy	of 176

It seems like another company has entered the Bloodless Glucose Monitoring field. See the post below. biz.yahoo.com The advantages to Elan of this is agreement is not apparant. " this joint venture will be 80.1 percent owned by Bioject and 19.9 percent owned by Elan" "After the commencement of human clinical trials or April 1, 1998, which ever comes first, responsibility for funding further development costs will pass from Elan to the joint venture." If Elan chooses to put it's muscle behind it, the company has financial resources the other "bloodless glucose monitor" companies do not. A look at the company profile showed a market value of $5 Bil, and estimated 1998 profits of $200 million. I have no insight onto which of the companies has the best chance of being first to market, or being the eventual market winner. Best of luck on your investments. JL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next